Atlas Trials

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Clinical trial NCT04235933 · COMPLETED

Trial details

NCT number
NCT04235933
Sponsor
RemeGen Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2019-09-17
Primary completion
2019-12-20
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.